Stock Analysis
Genfit (EPA:GNFT) Full Year 2023 Results
Key Financial Results
- Revenue: €38.2m (up 46% from FY 2022).
- Net loss: €28.9m (loss widened by 22% from FY 2022).
- €0.58 loss per share (further deteriorated from €0.48 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Genfit Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 38%. Earnings per share (EPS) also missed analyst estimates by 3.7%.
In the last 12 months, the only revenue segment was Research and Development of Innovative Medicines and Diagnostic Solutions contributing €38.2m. The largest operating expense was Research & Development (R&D) costs, amounting to €46.5m (69% of total expenses). Explore how GNFT's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in France.
Performance of the French Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Genfit's balance sheet and an in-depth analysis of the company's financial position.
Valuation is complex, but we're helping make it simple.
Find out whether Genfit is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:GNFT
Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
Undervalued with high growth potential.
